BC Extra | Nov 21, 2019
Company News

Alnylam unveils pricing strategy for second FDA-approved RNAi drug

Alnylam unveiled a performance-based and prevalence-based pricing strategy to mitigate risks to participating payers covering RNAi therapy Givlaari givosiran, which FDA approved more than two months ahead of schedule for adults with acute hepatic porphyria....
BC Extra | Nov 18, 2019
Clinical News

Heart failure notches another win as Merck, Bayer's sGC stimulator meets in Phase III

Another new mechanism for heart failure passed a major hurdle as partners Merck and Bayer announced Monday that vericiguat met the primary endpoint in the Phase III VICTORIA trial in patients with worsening chronic heart...
BC Extra | Oct 30, 2019
Company News

Oct. 30 Company Quick Takes: Clinical hold for Zolgensma; plus Biogen-Alkermes, Roche’s satralizumab, Pear-Ironwood

Partial hold for Novartis’ SMA gene therapy  FDA placed a partial clinical hold on studies of intrathecally delivered Zolgensma onasemnogene abeparvovec-xioi from Novartis AG (NYSE:NVS; SIX:NOVN) to treat spinal muscular atrophy after observing dorsal root...
BC Extra | Oct 30, 2019
Clinical News

Ironwood spinout sees path forward for platform despite lead program miss

Two failed Phase II trials of its most advanced candidate sent Cyclerion tumbling just months after the company’s split from Ironwood. Despite the miss for praliciguat, the company sees signs of optimism for the platform....
BC Extra | Sep 20, 2019
Company News

Sept. 20 Company Quick Takes: Three Japanese approvals, plus AZ-Ironwood, Boehringer-Inflammasome, China Biologics and a Sino-Russian JV

Japanese approvals include Tecentriq for TNBC  Japan’s Ministry of Health, Labour and Welfare expanded the label of Tecentriq atezolizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) to include PD-L1-positive triple-negative breast cancer. MHLW also approved serotonin...
BC Extra | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

Ironwood, Clovis price note deals  Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) raised $350 million in a convertible notes offering, including $175 million in 0.75% notes maturing in June 2024 and $175 million in 1.5% notes maturing June...
BC Extra | Jul 26, 2019
Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

Obsidian Therapeutics (Cambridge, Mass.) hired Catherine Stehman-Breen as chief development officer, Ryan Daws as CFO, and Karen Brown as SVP, intellectual property and legal affairs. Stehman-Breen was CMO of Atlas Venture-backed Dyne Therapeutics Inc. (Cambridge,...
BC Extra | Jun 19, 2019
Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

G1 rises on trilaciclib OS efficacy in Phase II for TNBC  G1 Therapeutics Inc. (NASDAQ:GTHX) has gained 33% to $26.27 since reporting preliminary data Tuesday from a Phase II trial showing a statistically significant improvement...
BC Innovations | May 20, 2019
Distillery Therapeutics

Cyclerion's sGC stimulator praliciguat ameliorates NASH in rodents

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH) Rat and mouse studies suggest the systemic sGC stimulator praliciguat could help treat NASH. In liver samples from patients, levels of an sGC subunit were higher in fibrotic...
BC Extra | May 15, 2019
Financial News

May 15 Financial Quick Takes: Perceptive leads $60M round for ArcherDx; plus Applied Therapeutics’ IPO, IsoPlexis, Symphogen

ArcherDx completes $60M series B  New investor Perceptive Advisors led a $60 million series B round for ArcherDx Inc. (Boulder, Colo.) that the company plans to use to scale operations, advance its companion diagnostic program...
Items per page:
1 - 10 of 390
BC Extra | Nov 21, 2019
Company News

Alnylam unveils pricing strategy for second FDA-approved RNAi drug

Alnylam unveiled a performance-based and prevalence-based pricing strategy to mitigate risks to participating payers covering RNAi therapy Givlaari givosiran, which FDA approved more than two months ahead of schedule for adults with acute hepatic porphyria....
BC Extra | Nov 18, 2019
Clinical News

Heart failure notches another win as Merck, Bayer's sGC stimulator meets in Phase III

Another new mechanism for heart failure passed a major hurdle as partners Merck and Bayer announced Monday that vericiguat met the primary endpoint in the Phase III VICTORIA trial in patients with worsening chronic heart...
BC Extra | Oct 30, 2019
Company News

Oct. 30 Company Quick Takes: Clinical hold for Zolgensma; plus Biogen-Alkermes, Roche’s satralizumab, Pear-Ironwood

Partial hold for Novartis’ SMA gene therapy  FDA placed a partial clinical hold on studies of intrathecally delivered Zolgensma onasemnogene abeparvovec-xioi from Novartis AG (NYSE:NVS; SIX:NOVN) to treat spinal muscular atrophy after observing dorsal root...
BC Extra | Oct 30, 2019
Clinical News

Ironwood spinout sees path forward for platform despite lead program miss

Two failed Phase II trials of its most advanced candidate sent Cyclerion tumbling just months after the company’s split from Ironwood. Despite the miss for praliciguat, the company sees signs of optimism for the platform....
BC Extra | Sep 20, 2019
Company News

Sept. 20 Company Quick Takes: Three Japanese approvals, plus AZ-Ironwood, Boehringer-Inflammasome, China Biologics and a Sino-Russian JV

Japanese approvals include Tecentriq for TNBC  Japan’s Ministry of Health, Labour and Welfare expanded the label of Tecentriq atezolizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) to include PD-L1-positive triple-negative breast cancer. MHLW also approved serotonin...
BC Extra | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

Ironwood, Clovis price note deals  Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) raised $350 million in a convertible notes offering, including $175 million in 0.75% notes maturing in June 2024 and $175 million in 1.5% notes maturing June...
BC Extra | Jul 26, 2019
Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

Obsidian Therapeutics (Cambridge, Mass.) hired Catherine Stehman-Breen as chief development officer, Ryan Daws as CFO, and Karen Brown as SVP, intellectual property and legal affairs. Stehman-Breen was CMO of Atlas Venture-backed Dyne Therapeutics Inc. (Cambridge,...
BC Extra | Jun 19, 2019
Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

G1 rises on trilaciclib OS efficacy in Phase II for TNBC  G1 Therapeutics Inc. (NASDAQ:GTHX) has gained 33% to $26.27 since reporting preliminary data Tuesday from a Phase II trial showing a statistically significant improvement...
BC Innovations | May 20, 2019
Distillery Therapeutics

Cyclerion's sGC stimulator praliciguat ameliorates NASH in rodents

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH) Rat and mouse studies suggest the systemic sGC stimulator praliciguat could help treat NASH. In liver samples from patients, levels of an sGC subunit were higher in fibrotic...
BC Extra | May 15, 2019
Financial News

May 15 Financial Quick Takes: Perceptive leads $60M round for ArcherDx; plus Applied Therapeutics’ IPO, IsoPlexis, Symphogen

ArcherDx completes $60M series B  New investor Perceptive Advisors led a $60 million series B round for ArcherDx Inc. (Boulder, Colo.) that the company plans to use to scale operations, advance its companion diagnostic program...
Items per page:
1 - 10 of 390